Crystalline Carbamate Solid Forms for Predictable Ocular Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Different solid forms of a drug, such as amorphous and crystalline forms, exhibit varying properties affecting dissolution, bioavailability, and handling, making it challenging to predict and manage their characteristics, which is crucial for optimal drug administration and regulatory approval.
Innovation Solution
Development of specific crystalline forms of 3-(4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate and its pharmaceutically acceptable salts, including acetate, benzoate, hydrochloride, and phosphate, which are characterized by unique XRPD patterns and melting points, enabling predictable pharmaceutical compositions and methods for treating vision-related disorders like glaucoma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple solid forms of a drug are developed to optimize dissolution and bioavailability, then drug delivery performance is improved, but the complexity of identifying and characterizing all forms increases
Solution Approach 1:
The patent applies preliminary action by conducting comprehensive solid form characterization and identification before regulatory submission. The invention systematically identifies, characterizes, and evaluates multiple crystalline forms, amorphous forms, and salts of the drug substance in advance, establishing a complete picture of the drug's solid state behavior before product development proceeds. This proactive approach ensures all relevant solid forms are known and characterized, eliminating the need for additional experimentation during regulatory review.
2Loss of information
If comprehensive experimentation is conducted to identify all crystalline forms, then complete drug characterization is achieved, but time and resource consumption increase
Solution Approach 1:
The patent applies parameter changes by systematically varying experimental conditions such as solvent type, temperature, pH, and crystallization rates to induce different solid forms. By changing these parameters methodically, the invention identifies all possible crystalline polymorphs, amorphous forms, and salts without requiring exhaustive trial-and-error experimentation. This structured parameter exploration efficiently maps the complete solid state landscape of the drug substance.
3Reliability
If all solid forms are identified and characterized before approval, then regulatory compliance is improved, but the manufacturing process becomes more complex
Solution Approach 1:
The patent applies local quality by selecting specific solid forms with optimized properties for different manufacturing purposes and therapeutic indications. Rather than treating all solid forms equally, the invention identifies which crystalline forms, amorphous forms, or salts possess the most favorable combination of dissolution rate, stability, and manufacturability for each specific application. This selective approach allows optimization of manufacturing processes for the chosen form while maintaining regulatory compliance through complete characterization of all forms.
Data Source
AI summary
Solid forms of 3-(4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate and salts thereof are disclosed. Methods of its use to treat diseases and disorders of the eye are also disclosed.